Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021

Rhea-AI Summary

Osmotica Pharmaceuticals (Nasdaq: OSMT) will present at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:00 a.m. Eastern Time. CEO Brian Markison, COO JD Schaub, and CFO Andrew Einhorn will lead the presentation, which will be available via live webcast and archived for 30 days on Osmotica’s website. The company focuses on developing and commercializing products for underserved patient populations, with their recent launch of UPNEEQ, approved for treating droopy eyelids in adults.

BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows:

Date:		Monday, September 27, 2021
Time:		10:00 a.m. Eastern Time
Webcast:		https://wsw.com/webcast/cantor12/osmt/2117150

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.

About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations. In July 2020, the Company received regulatory approval from the U.S Food and Drug Administration for RVL-1201, or UPNEEQ^® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults. UPNEEQ was commercially launched September 2020 through RVL Pharmaceuticals, Inc., the Company’s ophthalmic subsidiary, to a limited number of eye care professionals with commercialization operations expanded in 2021 among ophthalmology, optometry and oculoplastic specialties.

Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When is Osmotica Pharmaceuticals presenting at the Cantor Virtual Global Healthcare Conference?

Osmotica Pharmaceuticals will present at the conference on September 27, 2021, at 10:00 a.m. Eastern Time.

Who will represent Osmotica Pharmaceuticals at the Cantor conference?

Brian Markison, JD Schaub, and Andrew Einhorn will represent Osmotica Pharmaceuticals at the conference.

How can I watch the Osmotica Pharmaceuticals presentation?

The presentation can be watched live and archived for 30 days via the webcast link on Osmotica's website.

What is the focus of Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals focuses on developing and commercializing products for underserved patient populations.

What product did Osmotica Pharmaceuticals launch recently?

Osmotica Pharmaceuticals recently launched UPNEEQ, an FDA-approved treatment for droopy eyelids.